ENZON PHARMACEUTICALS INC
Latest Quote @ Tue Jun 6 20:19:50 (15 min delayed)
Last Day's Data
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the ‘Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.